Natural History of Levodopa-Induced Dyskinesia (LID)
Natural History of Levodopa-Induced Dyskinesia (LID)
Levodopa is the main drug treatment for Parkinson's disease. Levodopa can cause unwanted and
 uncontrolled movements called dyskinesias (LID). The severity of these movements can range
 from subtle to extremely debilitating. These movements may or may not interfere with normal
 activities such as putting on a coat or brushing ones teeth. Current estimates of the
 occurrence rate of LID range from 12 % to 100% after one year of levodopa treatment. These
 estimates used reporting mechanisms such as self-report and doctor-reported. These reporting
 mechanisms are not reliable. We will use an objective measure of dyskinesia in the first 5
 years of treatment for Parkinson's disease. The purpose of this protocol is to use an
 objective measure to estimate dyskinesia onset.
Nearly all Parkinson's disease (PD) patients eventually develop abnormal and unwanted
 movements (dyskinesias; LID) caused by the gold standard treatment, Levodopa. The severity of
 these movements can range from subtle to extremely debilitating and may or may not interfere
 with normal activities such as putting on a coat or brushing ones teeth. Current estimates of
 the prevalence of LID widely range from 12 % to 100% affected after one year. The purpose of
 this study is to estimate the median onset time of levodopa induced dyskinesia in newly
 treated Parkinson's disease patients. All participants will complete seven overnight visits
 at the OCTRI Inpatient unit over 5 years. During the next day, participants will complete a
 mental task while standing on a force plate for one minute every half hour until the end of
 the study. A levodopa IV infusion will occur from 0900 to 1100.
Inclusion Criteria:

 -  Diagnosis of Parkinson's disease

 -  At least 21 years of age

 -  Levodopa treatment that will be orally initiated no more than 1 month after the
 screening visit for the study.

 Exclusion Criteria:

 -  Unable to stand for 1 minute intervals

 -  Sensory deficits in the feet

 -  Significant cognitive impairment

 -  Unstable medical or psychiatric conditions (including hallucinations)

 -  History of dopamine receptor blocking medications (Haldol, Orap, Zyprexa)